People with Lambert-Eaton myasthenic syndrome (LEMS) have a lower quality of life and a higher disease burden than do those with myasthenia gravis (MG) or adults in the general population, according to a survey-based study in Germany. “Quality of life reflects one aspect of the burden of disease.
The U.S. Food and Drug Administration (FDA) has approved increasing from 80 to 100 mg the maximum recommended daily dose of Firdapse (amifampridine) for adults and children weighing at least 45 kg (about 99 pounds) with Lambert-Eaton myasthenic syndrome (LEMS). The decision follows a supplemental new drug application…
A man in his 60s who developed Lambert-Eaton myasthenic syndrome (LEMS) secondary to prostate cancer saw his neurological symptoms ease after receiving treatment with amifampridine — the active ingredient in the approved LEMS therapy Firdapse. That’s according to a report detailing the man’s case, unusual, per the researchers,…
The inaugural Lambert-Eaton myasthenic syndrome (LEMS) Awareness Day — which will be held each year on March 30 to call attention to the rare autoimmune disorder — was “fantastic,” according to the nonprofit association that created the event. “We appreciate everything everyone did for this first LEMS Awareness Day,…
The lack of a reflex response that was relieved temporarily after exercise, a phenomenon known as post-exercise facilitation, is an early sign of Lambert-Eaton myasthenic syndrome (LEMS), a case report suggests. The report described the case of a woman, 62, who had a neuroendocrine tumor in the gallbladder…
The rare case of a man with lung cancer complicated by two co-occurring cancer-associated syndromes — Lambert-Eaton myasthenic syndrome (LEMS) and syndrome of inappropriate antidiuretic hormone secretion (SIADH) — was described in a recent report. According to its scientists, only four other documented reports of LEMS and SIADH developing…
DyDo Pharma is seeking approval of Firdapse (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS) in Japan. A decision from Japan’s Pharmaceuticals and Medical Devices Agency is expected in September. DyDo’s application was submitted in collaboration with Catalyst Pharmaceuticals, which developed Firdapse. DyDo is leading the development…
The rare case of a man with Lambert-Eaton myasthenia syndrome (LEMS) that co-occurred with non-Hodgkin lymphoma, a type of immune cell cancer, was described in a recent report. “In this case report, we present the case of a 57-year-old male diagnosed with non-Hodgkin’s lymphoma (NHL) who developed LEMS, an…
The U.S. Patent and Trademark Office has sent a notice of allowance for two additional patents for Firdapse (amifampridine), Catalyst Pharmaceuticals’ approved therapy for Lambert-Eaton myasthenic syndrome (LEMS), for claims related to its bioavailability under fasting and fed dosing conditions. Catalyst, which has licensing rights in North…
The U.S. Food and Drug Administration (FDA) has agreed to review Catalyst Pharmaceuticals’ request to raise to 100 mg the maximum recommended daily dose of Firdapse (amifampridine), its approved treatment for Lambert-Eaton myasthenic syndrome (LEMS). Firdapse’s label allows for an 80 mg maximum daily dose…
Get regular updates to your inbox.